KURN Stock Overview
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kuros Biosciences AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF2.15 |
| 52 Week High | CHF2.86 |
| 52 Week Low | CHF1.11 |
| Beta | 0.95 |
| 1 Month Change | 13.16% |
| 3 Month Change | 66.67% |
| 1 Year Change | 22.86% |
| 3 Year Change | -14.00% |
| 5 Year Change | -61.61% |
| Change since IPO | -92.83% |
Recent News & Updates
We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Sep 17
Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues
Jun 28Recent updates
We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Sep 17Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues
Jun 28Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation
May 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Jun 11Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now
Apr 12Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years
Mar 02What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay
Nov 17
Shareholder Returns
| KURN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | -1.4% | -0.3% | -1.5% |
| 1Y | 22.9% | -40.6% | 7.5% |
Return vs Industry: KURN exceeded the Swiss Biotechs industry which returned -41.6% over the past year.
Return vs Market: KURN exceeded the Swiss Market which returned 6.8% over the past year.
Price Volatility
| KURN volatility | |
|---|---|
| KURN Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in CH Market | 7.2% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: KURN is more volatile than 90% of Swiss stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: KURN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 73 | Joost de Bruijn | https://www.kuros.ch |
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company’s orthobiologics pipeline products include MagnetOs Granules, MagnetOs Putty, MagnetOs Easypack Putty, and MagnetOs Flex Matrix in EU and US for the treatment of orthopedics, spinal, and dental problems.
Kuros Biosciences AG Fundamentals Summary
| KURN fundamental statistics | |
|---|---|
| Market Cap | CHF78.57m |
| Earnings (TTM) | -CHF15.95m |
| Revenue (TTM) | CHF20.43m |
3.8x
P/S Ratio-4.9x
P/E RatioIs KURN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KURN income statement (TTM) | |
|---|---|
| Revenue | CHF20.43m |
| Cost of Revenue | CHF12.44m |
| Gross Profit | CHF7.99m |
| Other Expenses | CHF23.94m |
| Earnings | -CHF15.95m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 39.11% |
| Net Profit Margin | -78.07% |
| Debt/Equity Ratio | 0% |
How did KURN perform over the long term?
See historical performance and comparison